European Primary Care Cardiovascular Society

Heart Failure

Follow the news, literature, and elearning on new developments in the management of Heart Failure.

Screening for AF, HF and CAD in primary care

5' education - June 16, 2020 - Victor Zwartkruis

sGC stimulator has added value in worsening HFrEF patients

3' education - Apr. 10, 2020 - Prof. Paul Armstrong, MD - ACC 2020

ARNI seems to give CV benefit up to EF of about 60%, not only in HFrEF

3' education - Nov. 16, 2019 - Scott Solomon, Boston - AHA 2019, Philadelphia

Does HF have two physiologies that respond differently to treatment, or is it the same disease across the EF spectrum?

3' education - Nov. 18, 2019 - Lynne Stevenson, Nashville - AHA 2019, Philadelphia

SGLT2 inhibitor improves health status in HFrEF

3' education - Nov. 17, 2019 - Mikhail Kosiborod, Kansas City - AHA 2019, Philadelphia
EPCCS Annual CV Summit

Heart failure and comorbidities: kidney disease and cancer

5' education - Mar. 22, 2019 - Lisbon, Portugal - Peter van der Meer & Monika Hollander

SGLT2 inhibitor greatly reduced CV risk in HFrEF with or without diabetes

3' education - Sep. 16, 2019 - Paris, France - Prof. John McMurray
EPCCS Annual CV Summit

New diagnostic algorithm and therapeutic options in HF management

5' education - Mar. 22, 2019 - Lisbon, Portugal - Peter van der Meer & Monika Hollander

EPCCS

3' education - Feb. 8, 2019

HFpEF: What is it & size of the problem

10' education - Aug. 27, 2018 - Prof. Adriaan Voors - Groningen, The Netherlands

Complexities of managing heart failure

10' education - Mar. 16, 2018 - EPCCS 2018, Barcelona, Spain - Dr. Clare Taylor, Dr. Nuria Farré and Dr. Frans Rutten
##SCROLLER_ITEMS_FULL_TITLE##

Heart failure diagnosis and management varies substantially across European countries

10' education - May 25, 2017
##SCROLLER_ITEMS_FULL_TITLE##

Heart failure diagnosis and management

10' education - Dec. 9, 2015 - EPCCS 2015 - Prague

Increased risk of adverse outcomes in HFmrEF with LVEF deterioration into midrange

Literature - July 29, 2020 - Brann A et al., - JAMA Cardiol. 2020.

Patients whose LVEF deteriorated from normal to midrange levels had a significantly higher risk of adverse clinical outcomes compared to those whose LVEF had improved from lower values.

Comprehensive disease-modifying pharmacological therapies reduce CV events in HFrEF

Literature - July 1, 2020 - Vaduganathan M et al., - The Lancet. 2020.

This cross-trial analysis estimated that comprehensive disease-modifying pharmacological therapy in HFrEF patients reduces the hazard of CV death or hospital admission, compared with conventional therapy.

An 11-item questionnaire to screen for AF, HF, and CAD in primary care

Literature - June 16, 2020 - Zwartkruis VW et al., - Prev Med. 2020.

A diagnostic model based on symptoms partly uncovered unrecognized AF, HF and CAD in participants from the Lifelines cohort study. This resulted in the development of an 11-item questionnaire for proactive screening.

Screening for AF, HF and CAD in primary care

5' education - June 16, 2020 - Victor Zwartkruis
A diagnostic model with data from the Lifelines cohort study improved early detection of unrecognized AF, HF and CAD in primary care. This translated into the development of a patient questionnaire.

A diagnostic model with data from the Lifelines cohort study improved early detection of unrecognized AF, HF and CAD in primary care. This translated into the development of a patient questionnaire.

Novel selective cardiac myosin activator in HF gets FDA Fast Track designation

News - June 2, 2020

Omecamtiv mecarbil, a cardiac myosin activator or cardiac myotrope, has been granted Fast Track designation by the FDA for treatment of HFrEF patients.

Lowest risk of outcomes in HFpEF associated with SBP of 120-129 mmHg

Literature - May 28, 2020 - Selvaraj S et al., - J Am Coll Cardiol. 2020

This study showed that a SBP of 120 to 129 mmHg was associated with the lowest risk of adverse outcomes in HFpEF. SBP lowering does not explain the treatment effects of sacubitril/valsartan.

FDA approves SGLT2i for treatment of HFrEF patients

News - May 12, 2020

The FDA approved dapagliflozin for treatment of heart failure patients with reduced ejection fraction to reduce CV death and hospitalization for HF.

sGC stimulator has added value in worsening HFrEF patients

3' education - Apr. 10, 2020 - Prof. Paul Armstrong, MD - ACC 2020
The soluble guanylate cyclase stimulator vericiguat reduced CV death and HF hospitalization compared to placebo in HFrEF patients with worsening HF.

ACC 2020 The soluble guanylate cyclase stimulator vericiguat reduced CV death and HF hospitalization compared to placebo in HFrEF patients with worsening HF.

In HFrEF patients with worsening HF, sGC stimulator reduces CV death and HF hospitalization

News - Apr. 10, 2020

ACC 2020 The VICTORIA trial demonstrated that therapy with the sGC stimulator vericiguat reduced the primary endpoint in HFrEF patients with worsening HF condition compared to placebo.

ARNI use in elderly HFrEF patients is safe and effective

Literature - Jan. 13, 2020 - Esteban-Fernández A et al., - Rev Esp Geriatr Gerontol. 2019.

This prospective registry study of a real-world cohort of elderly HFrEF patients showed that sacubitril/valsartan was safe and effective, even in those >80 years.

ARNI seems to give CV benefit up to EF of about 60%, not only in HFrEF

3' education - Nov. 16, 2019 - Scott Solomon, Boston - AHA 2019, Philadelphia
A prespecified analysis of PARADIGM-HF and PARAGON-HF data allowed assessment of the effect of sacubitril/valsartan across the spectrum of ejection fractions.

AHA 2019 A prespecified analysis of PARADIGM-HF and PARAGON-HF data allowed assessment of the effect of sacubitril/valsartan across the spectrum of ejection fractions.

Does HF have two physiologies that respond differently to treatment, or is it the same disease across the EF spectrum?

3' education - Nov. 18, 2019 - Lynne Stevenson, Nashville - AHA 2019, Philadelphia
As a discussant of the pooled PARAGON-HF and PARADIGM-HF data, dr. Stevenson critically considers the results to get physiological clues on who should be treated and who may not benefit of ARNI therapy.

AHA 2019 As a discussant of the pooled PARAGON-HF and PARADIGM-HF data, dr. Stevenson critically considers the results to get physiological clues on who should be treated and who may not benefit of ARNI therapy.